Nitazoxanide (Nitazoxanide) Patent Expiration, LOE Window & CMS Spending

Nitazoxanide (Nitazoxanide) by Rising: Multi-Source Generic Molecule, 3 AB generics, $5.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRising
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$5.4M
2024 Medicare Part D Spend$4.1M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 122.2% 2-yr change)